These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10429230)

  • 1. Sugen's strategy: a signal for P&U purchase.
    Glaser V
    Nat Biotechnol; 1999 Aug; 17(8):745-6. PubMed ID: 10429230
    [No Abstract]   [Full Text] [Related]  

  • 2. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 3. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer pathways' target not validated by clinical results.
    Ratner M
    Nat Biotechnol; 1999 Mar; 17(3):220. PubMed ID: 10096279
    [No Abstract]   [Full Text] [Related]  

  • 5. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 6. When a long shot is worth a shot.
    Jacobs T; Fischer J
    Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
    [No Abstract]   [Full Text] [Related]  

  • 7. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 9. IPO floodgates unlikely to open after Ark floatation.
    Louët S
    Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
    [No Abstract]   [Full Text] [Related]  

  • 10. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
    Fiorino T
    J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 12. The socialite scientist.
    Serwer A
    Fortune; 2002 Apr; 145(8):152-4, 158, 160 passim. PubMed ID: 11961885
    [No Abstract]   [Full Text] [Related]  

  • 13. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 14. Keys to CRM success. How well are contract pharmaceutical companies doing in the CRM game?
    Kros JF; Molis J
    Mark Health Serv; 2004; 24(4):32-6. PubMed ID: 15612224
    [No Abstract]   [Full Text] [Related]  

  • 15. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 16. Silent running: the race to the clinic.
    Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
    [No Abstract]   [Full Text] [Related]  

  • 17. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech's next big blowup?
    Stires D
    Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
    [No Abstract]   [Full Text] [Related]  

  • 19. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 20. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.